Targeting Agent
And Cancer Type

No. of.
Pts

Results

No. of toxicities
Grade 3/4

Ref.

Bevacizumab

Ovarian Cancer

CYC 50 mg od + BEV 10 mg/kg q²w

9

6/9 non-PD

hematuria 1/0
abdom. pain 1/0

84

 CYC 50 mg od + BEV 10 mg/kg q²w

1

Non-PD

no

85

CYC 50 mg od + BEV 10 mg/kg q²w

70

17/70 non-PD

hypertension 11/0
gastrointestinal perforation 0/2
lymphopenia 12/2

86

Breast Cancer

CYC 50 mg od + MTX 1 mg/kg iv q²w + BEV 10 mg/kg iv q²w +/- Trastuzumab in HER2-overexpressing tumors.

24

15/24 non-PD

thrombopenia 1/0

87

CAP 3x500 mg od + CYC 50 mg od + BEV 10 mg/kg q²w

46

41/46 non-PD

G 3+4 combined
hypertension 8
ASAT/ALAT ↑ 2

88

Glioblastoma

BEV 10 mg/kg KG q²w + VP-16 50mg/m2d1-21, qd29

59

53/59 non-PD

neutropenia 9/5
thrombosis 4/2
infection 4/1
hypertension 1/1

89

Imatinib

Hepatocellular Cancer

Trial 1
Group 1: Ocreotide 30 mg d1
Group 2: Ocreotide 30 mg d1 + Imatinib 400 mg od
Trial2
Group 3: OXA 60-90 mg/m²d1,
Group 4: OXA 20-30 mg/m²d1,8,15 + Ocreotide 30 mg d1 + Imatinib 400 mg od

38

Decelerated increase of biomarkers linked to angiogenesis like PDGF with Imatinib-Ocreotide.

1/38 non-PD

not published

90

Lapatinib

Breast Cancer

CAP 3 x 500 mg + Lapatinib 1250 mg od

1

non-PD

no

91

Rituximab

Mantle Cell Lymphoma

Induction (months 1–3) weekly Rituximab × 4, THAL 50 mg od, maintenance THAL 100 mg od + Pred 20 mg od + VP-16 50
mg od + PCZ 50 mg od + CYC 50 mg od (PEPC)

22

20/22 non-PD

G 3+4 combined
neutropenia 16
tromboses 2 infections 5

92

Sorafenib

Renal Cell Carcinoma

GEM 1000 mg/m²d1+8, CAP 2x500 mg d1-14, Sorafenib 400 mg bid d1-21for 6 cycles, followed by Sorafenib monotherapy

44

37/44 non-PD

fatigue 9/0
hfs-reaction 11/0
mucositis 3/0

1 Grade 5 dyspnoe

93

Hepatocellular Carcinoma

Sorafenib 400mg bid, tegafur/uracil 125mg/m²based on tegafur bid

53

30/56 non-PD

G 3+4 combined
fatigue 8
ASAT/ALAT ↑ 7
lipase ↑ 5

94

Trastuzumab

Breast Cancer

Trastuzumab 6 mg/kg q³w + MTX 2.5 mg bid d 1+ 4 q1w, CYC 50 mg od

22

14/22 non-PD

ASAT/ALAT ↑ 2/0

95